Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Liver transplant is indicated in patients with Wilson's disease for acute hepatic failure, advanced cirrhosis, and disease refractory to chelation therapy. This study aims to systematically review data about overall morbidity, hepatic, neuropsychiatric, and survival outcomes following liver transplantation for Wilson disease.
Methods: MEDLINE, Embase, and Central were searched from inception until July 2023. Peer-reviewed articles and published abstracts evaluating patients diagnosed with Wilson's disease and undergoing any type of liver transplant as a result of the disease were eligible for inclusion. A restricted maximum likelihood random effects model was used to generate the pooled proportion of each outcome. The risk of bias for each included observational study was assessed using the Methodological Index for Non-Randomized Studies tool.
Results: A total of 39 studies met all inclusion criteria. All studies were observational. Specific indications for liver transplant were most commonly acute liver failure (36.73%), chronic liver failure (45.02%), and acute-on-chronic liver failure (8.35%). The pooled proportions of mortality at 30 days, 1, and 5 years were 0.10 (95% CI 0.08, 0.13; I = 16%), 0.11 (95% CI 0.09, 0.14; I = 37%), and 0.15 (95% CI 0.11, 0.20; I = 81%), respectively. The postoperative complication with the greatest prevalence was biopsy-proven acute rejection with a pooled proportion of 0.20 (95% CI 0.12, 0.31; I = 84%). The mean MINORS score for risk of bias for all studies was 8.19.
Conclusion: Overall, reporting quality and consistency of outcomes included in the studies was poor as assessed using the MINORS score. Pooled proportions for 30-day, 1- and 5-year mortality are similar, suggesting most postoperative deaths are acute in nature. Future research should incorporate objective measures and the reporting of standardized parameters to allow more robust comparisons between studies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12128750 | PMC |
| http://dx.doi.org/10.1111/ctr.70155 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plasma Glial Fibrillary Acidic Protein Correlates With Brain Metal Burden in Wilson's Disease.
Ann Clin Transl Neurol
September 2025
Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
Objective: Neuroinflammation driven by extracellular copper contributes to neuronal damage in Wilson's disease (WD). This study investigated the relationship between brain metal burden and peripheral neuroinflammation markers in WD.
Methods: We conducted a cross-sectional study involving 89 participants, including patients with WD (n = 63), asymptomatic ATP7B heterozygous carriers (n = 12), and age/sex-matched controls (n = 14).
Diagnosis and Potential Therapy of Brain Diseases Using 64Cu: A Scoping Review.
Curr Med Chem
August 2025
Shanghai Key Lab of Forensic Medicine, Key Lab of Forensic Science, Ministry of Justice, China (Academy of Forensic Science), Shanghai, 200063, China.
Introduction: This paper provides a comprehensive review examining the application of copper radionuclides, particularly 64Cu, in the diagnosis and potential therapy of various brain diseases.
Methods: Two researchers conducted an independent search of the PubMed and Web of Science databases for original research articles published in English. Following a screening process based on titles and abstracts, 42 publications reporting the use of copper radionuclides for diagnosing or treating brain diseases were selected for this review.
The anthelmintic praziquantel (PZQ) has been used for decades as the clinical therapy for schistosomiasis, and remains the only available drug. As a cheap and effective drug therapy for all human disease-causing species, usage of PZQ underpins mass drug administration strategies aimed at eliminating schistosomiasis as a public health problem by 2030. Concern over the potential emergence of resistance to PZQ is therefore warranted, as it would constitute a major threat to this approach.
View Article and Find Full Text PDFSpot urinary copper/creatinine ratio: a non-invasive tool for diagnosis of Wilson's disease in children.
BMJ Paediatr Open
September 2025
Directorate General of Health Services, Dhaka, Bangladesh.
Diagnosing Wilson's disease (WD) in children remains a significant challenge. This study evaluated spot urinary copper/creatinine (Cu/Cr) ratio for paediatric WD diagnosis in Bangladesh. 60 children (30 WD, 30 non-WD by Leipzig criteria) were enrolled, and the spot morning urinary Cu/Cr and 24-hour urinary copper were measured.
View Article and Find Full Text PDFSystematic review of cardiac ventricular dysfunction in Wilson's disease: mechanisms, diagnostic advancements, and management strategies.
Future Cardiol
September 2025
Surgery, St. Anna Hospital, Herne, Germany.
Introduction: Wilson's disease (WD) is a rare autosomal recessive disorder caused by ATP7B gene mutations, leading to systemic copper accumulation. This systematic review examines the cardiac manifestations of WD and aims to summarize key diagnostic and therapeutic findings from available studies.
Methods: We conducted a systematic review of 21 studies using databases such as PubMed and Scopus.